Antibodies (Abs) that specifically block ICs, also named immune checkpoint inhibitors (ICIs), including anti-CTLA-4, anti-PD-1, and anti-PD-L1, are transforming cancer therapies by enhancing anti-cancer immunity. Here, CD274 is linked to cancer.